Abstract: A wiring module including a flexible printed wiring board to be electrically connected to a plurality of power storage elements, wherein the flexible printed wiring board includes: a base film that has insulating properties and has a first surface and a second surface; an adhesive layer that has adhesive properties and is stacked onto the first surface of the base film; a conductive path that is stacked onto the first surface of the base film using the adhesive layer; and a coverlay that is stacked onto the first surface of the base film using the adhesive layer, and covers the first surface of the base film and the conductive path, the conductive path has a fuse portion forming a part of a circuit and having a smaller cross-sectional area than another part of the conductive path, and a resin portion that includes a synthetic resin with insulating properties.

Abstract: A control device includes a memory; and a processor coupled to the memory. The processor is configured to acquire a status of each of a plurality of power distribution pathways provided at a moving body, and select a power distribution pathway having low resistance from among the plurality of power distribution pathways based on the acquired status, and cause power to be distributed via the selected power distribution pathway.

Abstract: A liquid level control apparatus includes a reception unit that receives information relating to an incoming direction of radiation; and a liquid control unit that controls, based on the received information relating to the incoming direction, liquid levels in a plurality of tanks that are provided around a device and that store a liquid, so that the liquid level in a tank positioned in the incoming direction relative to the device rises.

Abstract: A method for treating an adenocarcinoma excluding colon cancer, lung cancer and gastric cancer, comprising administering to a subject in need thereof and suffering from adenocarcinoma cancer, a pharmaceutically effective amount of at least one sulfoquinovosylacylglycerol compound represented by formula (1): wherein R101 represents an acyl residue of an unsaturated higher fatty acid, and R102 represents a hydrogen atom, and/or at least one pharmaceutically acceptable salt thereof.

Abstract: A method for treating a cancer. The cancer excluding an adenocarcinoma and being epithelioma, glioma, sarcoma, melanoma, lymphoma or leukemia; or the cancer is an adenocarcinoma cancer excluding colon cancer, lung cancer and gastric cancer. The method comprises administering to a subject in need thereof and suffering from cancer, a pharmaceutically effective amount of at least one sulfoquinovosylacylglycerol compound represented by formula (1): wherein R101 represents an acyl residue of an unsaturated fatty acid and R102 represents a hydrogen atom and/or at least one pharmaceutically acceptable salt thereof.

Abstract: A method for treating an adenocarcinoma excluding colon cancer, lung cancer and gastric cancer, comprising administering to a subject in need thereof and suffering from adenocarcinoma cancer, a pharmaceutically effective amount of at least one sulfoquinovosylacylglycerol compound represented by formula (1): wherein R101 represents an acyl residue of an unsaturated higher fatty acid, and R102 represents a hydrogen atom, and/or at least one pharmaceutically acceptable salt thereof.

Abstract: A medicament containing at least one compound selected from the group consisting of compounds represented by General formula (1): wherein R101 represents an acyl residue of an unsaturated higher fatty acid, and R102 represents a hydrogen atom or an acyl residue of an unsaturated higher fatty acid, and pharmaceutically acceptable salts thereof, as an active ingredient.

Abstract: Novel sulforhamnosylacylglycerol derivatives represented by General Formula (1): where R101 represents an acyl residue of a higher fatty acid and R102 represents a hydrogen atom or an acyl residue of a higher fatty acid. The derivatives represented by General formula (1) are useful as, a DNA polymerase inhibitor and an anticancer agent.

Abstract: Sulfofucosylacylglycerol derivatives represented by General Formula (1): where R101 represents an acyl residue of a higher fatty acid and R102 represents a hydrogen atom or an acyl residue of a higher fatty acid. The derivatives represented by General formula (1) are useful as a DNA polymerase inhibitor and an anticancer agent.

Abstract: A method for treating a cancer. The cancer excluding an adenocarcinoma and being epithelioma, glioma, sarcoma, melanoma, lymphoma or leukemia; or the cancer is an adenocarcinoma cancer excluding colon cancer, lung cancer and gastric cancer.

Abstract: An anticancer drug includes a compound represented by Formula (1): where R101 represents an acyl moiety of a saturated higher fatty acid, and R102 represents a hydrogen atom or an acyl moiety of a saturated higher fatty acid, and/or a pharmaceutically acceptable salt thereof.

Abstract: A method for immunosuppression in a subject comprising administering to the subject in need thereof, a pharmaceutically effective amount of at least one sulfoquinovosylacylglycerol derivative represented by General formula (1-1): wherein R101 represents an acyl residue of a higher fatty acid, and R102 represents a hydrogen atom or an acyl residue of a higher fatty acid; and a pharmaceutically acceptable salt thereof. Of the sulfoquinovosylacylglycerol derivatives, &bgr;-sulfoquinovosylacylglycerols are novel compounds. The present invention also relates to pharmaceutical composition comprising a pharmaceutically effective amount of the &bgr;-sulfoquinovosylacylglycerols and/or its pharmaceutically acceptable salt; and a pharmaceutically acceptable excipient. The pharmaceutical composition may be used as an immunosuppressive agent, anticancer agent and DNA polymerase &agr; inhibitor.

Abstract: An anticancer drug includes a compound represented by Formula (1): where R101 represents an acyl moiety of a saturated higher fatty acid, and R102 represents a hydrogen atom or an acyl moiety of a saturated higher fatty acid, and/or a pharmaceutically acceptable salt thereof.

Abstract: An anticancer drug includes a compound represented by Formula (1): 1

Abstract: 1-O-(2-propenyl)-6-O-sulfonylpyranoside represented by the formula wherein R1, R2 and R3 each independently represents an alkyl or substituted silyl group, and R4 represents an alkylsulfonyl or arylsulfonyl group.

Abstract: 1-O-(2-propenyl)-6-deoxy-6-carbonylthiopyranoside represented by the formula wherein R1, R2 and R3 each independently represents an alkyl or a substituted silyl group, and R5 represents a hydrogen atom, or an alkyl or aryl group.

Abstract: A method for immunosuppression in a subject comprising administering to the subject in need thereof, a pharmaceutically effective amount of at least one sulfoquinovosylacylglycerol derivative represented by General formula (1-1): 1

Abstract: Novel sulfofucosylacylglycerol derivatives represented by General Formula (1): 1

Abstract: A medicament containing at least one compound selected from the group consisting of compounds represented by General formula (1): 1

Abstract: Novel sulforhamnosylacylglycerol derivatives represented by General Formula (1): 1